Kodiak Sciences Inc. KOD
We take great care to ensure that the data presented and summarized in this overview for Kodiak Sciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KOD
View all-
Baker Bros. Advisors LP New York, NY17.3MShares$64.2 Million0.58% of portfolio
-
Black Rock Inc. New York, NY3.85MShares$14.3 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.95MShares$7.22 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$6.27 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.33MShares$4.92 Million0.01% of portfolio
-
Iconiq Capital, LLC San Francisco, CA1.27MShares$4.7 Million0.09% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.15MShares$4.25 Million0.78% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.07MShares$3.98 Million0.01% of portfolio
-
State Street Corp Boston, MA849KShares$3.15 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA794KShares$2.94 Million0.0% of portfolio
Latest Institutional Activity in KOD
Top Purchases
Top Sells
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Insider Transactions at KOD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2025
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
723
-0.39%
|
$2,169
$3.65 P/Share
|
|
Jun 15
2025
|
John A. Borgeson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.01%
|
-
|
|
Jun 17
2024
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
2,874
-1.55%
|
$5,748
$2.75 P/Share
|
|
Jun 15
2024
|
John A. Borgeson |
BUY
Exercise of conversion of derivative security
|
Direct |
5,494
+2.88%
|
-
|
|
Jun 12
2024
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
1,558
-0.86%
|
$3,116
$2.92 P/Share
|
|
Jun 11
2024
|
John A. Borgeson |
BUY
Exercise of conversion of derivative security
|
Direct |
3,025
+1.64%
|
-
|
|
Jun 16
2023
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
2,749
-1.52%
|
$24,741
$9.23 P/Share
|
|
Jun 16
2023
|
Jason Ehrlich Officer |
SELL
Open market or private sale
|
Direct |
2,258
-3.52%
|
$20,322
$9.23 P/Share
|
|
Jun 15
2023
|
John A. Borgeson |
BUY
Exercise of conversion of derivative security
|
Direct |
5,494
+2.95%
|
-
|
|
Jun 15
2023
|
Jason Ehrlich Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,494
+7.89%
|
-
|
|
Jun 14
2023
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
1,448
-0.82%
|
$13,032
$9.42 P/Share
|
|
Jun 14
2023
|
Jason Ehrlich Officer |
SELL
Open market or private sale
|
Direct |
1,132
-1.89%
|
$10,188
$9.42 P/Share
|
|
Jun 11
2023
|
John A. Borgeson |
BUY
Exercise of conversion of derivative security
|
Direct |
3,025
+1.68%
|
-
|
|
Jun 11
2023
|
Jason Ehrlich Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,900
+4.62%
|
-
|
|
Jun 17
2022
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
2,798
-1.58%
|
$19,586
$7.02 P/Share
|
|
Jun 17
2022
|
Jason Ehrlich Officer |
SELL
Open market or private sale
|
Direct |
2,282
-3.85%
|
$15,974
$7.02 P/Share
|
|
Jun 15
2022
|
John A. Borgeson |
SELL
Open market or private sale
|
Direct |
1,545
-0.87%
|
$10,815
$7.21 P/Share
|
|
Jun 15
2022
|
John A. Borgeson |
BUY
Exercise of conversion of derivative security
|
Direct |
5,494
+2.99%
|
-
|
|
Jun 15
2022
|
Jason Ehrlich Officer |
SELL
Open market or private sale
|
Direct |
1,205
-1.99%
|
$8,435
$7.21 P/Share
|
|
Jun 15
2022
|
Jason Ehrlich Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,494
+8.34%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.88K shares |
|---|
| Open market or private sale | 723 shares |
|---|